Mineralys Therapeutics Inc Sustainability Reports
Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension and chronic kidney diseases. Its lead product candidate is lorundrostat, an orally administered aldosterone synthase inhibitor.
Sector: Manufacturing
Country: United States
Exchange: Nasdaq
FIGI: BBG00ZXN1GR9
1 reports from 2024 to 2024
Company Profile
Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension and chronic kidney diseases. Its lead product candidate is lorundrostat, an orally administered aldosterone synthase inhibitor.
Reports
1 total
Limited sustainability disclosure available
This company only publishes Annual Reports without dedicated sustainability sections.
Years
